These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26093202)

  • 1. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
    Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
    Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
    Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
    Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
    Khurana S; Wu J; Verma N; Verma S; Raghunandan R; Manischewitz J; King LR; Kpamegan E; Pincus S; Smith G; Glenn G; Golding H
    J Virol; 2011 Nov; 85(21):10945-54. PubMed ID: 21865396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
    To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
    Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
    Khurana S; Coyle EM; Dimitrova M; Castellino F; Nicholson K; Del Giudice G; Golding H
    PLoS One; 2014; 9(4):e95496. PubMed ID: 24755693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.
    Khurana S; Chung KY; Coyle EM; Meijer A; Golding H
    J Virol; 2016 Oct; 90(20):9383-93. PubMed ID: 27512055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.
    Pedersen GK; Höschler K; Øie Solbak SM; Bredholt G; Pathirana RD; Afsar A; Breakwell L; Nøstbakken JK; Raae AJ; Brokstad KA; Sjursen H; Zambon M; Cox RJ
    Vaccine; 2014 Jul; 32(35):4550-4557. PubMed ID: 24950357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.
    Sun Z; Wang Q; Li G; Li J; Chen S; Qin T; Ma H; Peng D; Liu X
    Microbiol Spectr; 2021 Oct; 9(2):e0068721. PubMed ID: 34585985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice.
    Wang Y; Li Q; Peng P; Zhang Q; Huang Y; Hu J; Hu Z; Liu X
    Vet Microbiol; 2024 Jul; 294():110108. PubMed ID: 38729093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.
    Pan W; Han L; Dong Z; Niu X; Li Z; Bao L; Li C; Luo Q; Yang Z; Li X; Huang J; Feng L; Qin C; Zhong N; Chen L
    Antiviral Res; 2014 Jul; 107():1-5. PubMed ID: 24746458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
    Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
    Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
    El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
    Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.